Skip to navigation Skip to content

Acute myeloid leukaemia (AML) Program in Pharmaceutical Benefits Scheme (PBS) 012-18120338

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised azacitidine, daunorubicin+cytarabine, decitabine+cedazuridine and midostaurin for patients with acute myeloid leukaemia (AML).

AML and listing dates

AML is a type of cancer that affects the blood and bone marrow.

Listing dates:

  • azacitidine injection - 1 February 2011
  • midostaurin - 1 December 2018
  • decitabine+cedazuridine - 1 October 2022
  • azacitidine tablet - 1 September 2023
  • daunorubicin+cytarabine - 1 July 2024

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to:

  • PBS Complex Drugs Programs, and choose the option relevant to the condition treated (for azacitidine, daunorubicin+cytarabine and midostaurin)
  • PBS authority approvals line (for decitabine+cedazuridine)

The Resources page contains:

  • application forms
  • contact details
  • item and restriction codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority approval requests

Written Authority Required Drugs